Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers

Cindy Ke Zhou  
*National Cancer Institute, ke.zhou@nih.gov*

Frank Z. Stanczyk  
*University of Southern California, Los Angeles*

Muhannad Hafi  
*George Washington University*

Carmela C. Veneroso  
*George Washington University*

Barlow Lynch  
*Doctors Community Hospital*

See next page for additional authors

Follow this and additional works at: [http://digitalcommons.unl.edu/veterans](http://digitalcommons.unl.edu/veterans)
Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers

Cindy Ke Zhou1 | Frank Z. Stanczyk2 | Muhammad Hafi3 |
Carmela C. Veneroso3 | Barlow Lynch4 | Roni T. Falk1 | Shelley Niwa5 |
Eric Emanuel4 | Yu-Tang Gao6 | George P. Hemstreet7 | Ladan Zolfghari3 |
Peter R. Carroll8 | Michael J. Manyak9,10 | Isabell A. Sesterhenn11 |
Paul H. Levine12 | Ann W. Hsing13 | Michael B. Cook1

1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
2 Reproductive Endocrine Research Laboratory, Keck School of Medicine, University of Southern California, Los Angeles, California
3 Department of Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia
4 Doctors Community Hospital, Goddard, Maryland
5 Westat®, Rockville, Maryland
6 Department of Epidemiology, Shanghai Cancer Institute/Shanghai Jiao Tong University, Shanghai, China
7 Omaha Veterans Administration Medical Center, Omaha, Nebraska
8 Department of Urology, University of California, San Francisco, California
9 George Washington University, Washington, District of Columbia
10 GlaxoSmithKline, London, UK
11 Genitourinary Pathology, Joint Pathology Center, Silver Spring, Maryland
12 Department of Epidemiology, University of Nebraska Omaha, Omaha, Nebraska
13 Department of Medicine and Department of Health Research and Policy, Stanford Prevention Research Center/Cancer Institute, Stanford University, Stanford, California

Correspondence
Cindy Ke Zhou, PhD, Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute. 9609 Medical Center Drive Rm 6E330, Bethesda MD 20892-9774, USA.
Email: ke.zhou@nih.gov

Funding information
Intramural Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute

Background: Prospective cohort studies of circulating sex steroid hormones and prostate cancer risk have not provided a consistent association, despite evidence from animal and clinical studies. However, studies using male pattern baldness as a proxy of early-life or cumulative androgen exposure have reported significant associations with aggressive and fatal prostate cancer risk. Given that androgens underlie the development of patterned hair loss and chest hair, we assessed whether these two dermatological characteristics were associated with circulating and intraprostatic concentrations of sex steroid hormones among men diagnosed with localized prostate cancer.

Methods: We included 248 prostate cancer patients from the NCI Prostate Tissue Study, who answered surveys and provided a pre-treatment blood sample as well as fresh frozen adjacent normal prostate tissue. Male pattern baldness and chest hair density were assessed by trained nurses before surgery. General linear models estimated geometric means and 95% confidence intervals (95%CIs) of each hormone variable by dermatological phenotype with adjustment for potential confounding factors.
variables. Subgroup analyses were performed by Gleason score (<7 vs ≥7) and race (European American vs. African American).

**Results:** We found strong positive associations of balding status with serum testosterone, dihydrotestosterone (DHT), estradiol, and sex hormone-binding globulin (SHBG), and a weak association with elevated intraprostatic testosterone. Conversely, neither circulating nor intraprostatic sex hormones were statistically significantly associated with chest hair density. Age-adjusted correlation between binary balding status and three-level chest hair density was weak (r = 0.05). There was little evidence to suggest that Gleason score or race modified these associations.

**Conclusions:** This study provides evidence that balding status assessed at a mean age of 60 years may serve as a clinical marker for circulating sex hormone concentrations. The weak-to-null associations between balding status and intraprostatic sex hormones reaffirm differences in organ-specific sex hormone metabolism, implying that other sex steroid hormone-related factors (eg, androgen receptor) play important roles in organ-specific androgenic actions, and that other overlapping pathways may be involved in associations between the two complex conditions.

**Keywords**
chest hair density, male pattern baldness, prostate tissue, serum, sex steroid hormones

---

**1 | INTRODUCTION**

Androgens have long been hypothesized to underlie the development of prostate cancer. However, the association between serum sex steroid hormones and prostate cancer risk remains inconsistent. A meta-analysis of 18 prospective studies reported null associations using study-specific circulating concentrations, albeit limited by the use of blood at a single time-point after midlife that may have missed the etiologically relevant time window, and a potentially diluted effect through inclusion of a variable proportion of indolent prostate cancer cases in the era of prostate-specific antigen (PSA) testing. Later epidemiologic studies also did not support the association between circulating sex steroid hormones and prostate cancer risk, although some subgroup analyses reported a positive association of aggressive prostate cancer with total testosterone/sex hormone-binding globulin (SHBG) ratio, and an inverse association with the highest quintile of total estradiol/total testosterone ratio.

Despite the paucity of evidence for an association between circulating sex steroid hormones and prostate cancer risk, androgenic alopecia (also commonly known as male pattern baldness) used as a proxy for early-life or cumulative exposure to sex steroid hormones has been reported to be associated with aggressive and fatal prostate cancer. Male pattern baldness is the most common hair loss in men and affects approximately 50% of Caucasian men by age 50. Bald scalp overexpresses androgen receptor (AR) and has higher levels of dihydrotestosterone (DHT), compared with the non-bald region. This enhanced androgenic action induces miniaturization of scalp hair follicles and causes progressive hair loss. On the other hand, men born with 5α-reductase type II (5αR2, which intracellularly converts testosterone to DHT) deficiency, or castrated before puberty show complete retention of scalp hair. The former observation has led to the use of finasteride (a 5αR2 inhibitor) in balding treatment, which slows scalp hair loss and promotes new scalp hair growth.

Although no study has assessed the direct relationship between chest hair density and prostate cancer risk, associations between chest hair density and circulating sex steroid hormones have been reported. The development of chest hair parallels the surge of androgens in men during puberty. Denser chest hair has been correlated with higher levels of circulating 3α-androstanediol glucuronide (3α-diol-G; a metabolite of DHT in peripheral tissue) and lower SHBG concentrations. Given the role of androgenic action in these dermatological phenotypes, we investigated clinically assessed balding status and chest hair density in relation to circulating and intraprostatic concentrations of sex steroid hormones in the NCI Prostate Tissue Study in an attempt to understand the potential biological mechanisms underlying associations between the dermatological phenotypes and prostate cancer risk.

**2 | MATERIALS AND METHODS**

**2.1 | Study population**

A detailed description of the Prostate Tissue Study has been reported elsewhere. In brief, 422 patients were enrolled from five hospitals during January 2000 to April 2004. Eligible study subjects were men aged 18 years or older, scheduled for prostatectomy or
cystoprostatectomy, newly diagnosed with localized prostate cancer, and had not taken any medication that may influence sex steroid hormone concentrations (e.g., dehydroepiandrosterone [DHEA], finasteride, and neoadjuvant hormone therapy) during the 24 h preceding surgery.

Each patient provided 30 mL of fasting blood before surgery, which was aliquoted within 4 h at room temperature and subsequently frozen at −70°C. During surgery and immediately after the prostate gland was resected, the pathologist sliced a maximum of three pieces of macroscopically normal tissue from each of the peripheral and non-peripheral zones of the prostate, each piece weighing 200-400 mg. Each macroscopically normal tissue had the ends trimmed and fixed in formalin for Haemotoxylin and Eosin stain. A genitourinary pathologist (I.A.S.) subsequently evaluated the morphology and histology of these margins to rule out slices containing cancer. The remaining tissue was placed in a pre-labeled cryovial, flash frozen in liquid nitrogen and stored at −70°C.

Each patient underwent a physical examination before surgery by trained hospital nurses for anthropometric and dermatological information and a follow-up telephone interview approximately six weeks after surgery for information on demographics, medical history, family history of cancer, and lifestyle. Medical and pathology reports were also extracted.

2.2 Sex steroid hormone quantitation

Sex steroid hormones were quantified at the University of Southern California under the direction of F.Z.S. A detailed description of sample handling and laboratory process have been previously reported. In brief, serum concentrations of total testosterone (testosterone), DHT, 4-Androstene-3, 17-dione (androstenedione), estrone, and total estradiol (estradiol) were measured by in-house radioimmunoassays (RIA). 3α-diol-G was measured by a commercial RIA kit (Diagnostics Systems Laboratories, Webster TX, presently Beckman-Coulter, Minneapolis, MD), and SHBG was measured by a solid-phase, two-site chemiluminescent immunometric assay on the Immulite analyzer (Diagnostic Products Corporation, Los Angeles, CA, presently Siemens Healthcare Diagnostics, Deerfield, IL) during 2007. RIAs were used after organic solvent extraction to remove conjugated steroids and Celite column partition chromatography to separate potential interfering unconjugated steroids. In addition, highly specific antisera were used in the RIAs to provide added specificity. Concentrations of serum free testosterone and free estradiol were calculated using validated algorithms. Coefficients of variation (CV)—calculated on the logarithmic scale using a mixed model which included 2-7 replicates from each of seven different individuals—were all less than 15% (mean = 10%).

Intraprostatic sex steroid hormones, including androstenedione, testosterone, DHT, 3α-diol-G, estrone, and estradiol, were extracted from each homogenized prostate tissue sample weighing 100-400 mg during 2008-2009. These hormones then underwent the same preparation procedures and RIAs as in the serum hormone quantitation, and were expressed as picograms per gram of wet tissue weight. In-house assays for tissue hormones had small technical variability with CVs below 20% (mean = 13.8%) for all, except for androstenedione (21%). CVs were calculated on the logarithmic scale using a mixed model including an average of six technical replicates from each of five different individuals. For intraprostatic sex steroid hormone analysis, we used all eligible pieces of adjacent normal tissue regardless of sampling locations to calculate subject-level mean concentrations, as our pilot study of 30 prostate cancer patients showed that this provided generally superior CV and intra-class correlation coefficient (ICC) values, compared with using the mean concentrations of solely peripheral or solely non-peripheral tissue. Both serum and tissue sex steroids RIAs used tritiated internal standards, and the concentrations were corrected for procedural losses ranging from 15% to 30%.

2.3 Exposure measurement

Trained hospital nurses assessed scalp hair pattern using a Norwood-Hamilton Scale and grouped participants into three categories: 1) no/little baldness (I/II); 2) vertex baldness (III-vertex, IV/V/Va/VI, and VII); and 3) frontal baldness (Iia/Ii/Iiia/Iva) (Supplementary Figure S1). A previous validation study asked dermatologists and residents to rate balding patterns using Norwood-Hamilton scale against photographs of male heads, reporting modest ICCs (0.63-0.68) for original classes and recommending reduced classes to achieve higher ICCs. Therefore, the three-level balding variable was further collapsed into two categories: no/little versus any baldness to minimize potential misclassification. Chest hair density was originally measured on the Ferriman-Gallwey five-level scale (ie, none, sparse, moderate, dense, and very dense). A previous validation study reported good inter-observer agreement (kappa = 0.80) for the original scale among Turkish women. This variable was subsequently collapsed into three categories in the analysis: none-to-sparse (lowest two levels), moderate, and dense (highest two levels).

2.4 Analytic sample

Of 422 enrolled patients, we included 248 prostate cancer patients for this analysis, after excluding 148 without sex hormones assayed in tissue, 14 without a diagnosis of prostate cancer, one without serum hormones and 11 without any measured dermatological information.

2.5 Statistical analysis

Pearson χ² tests assessed independence of categorical patient characteristics from balding status and chest hair density. Partial Spearman's correlation coefficients were estimated for pairs of circulating and intraprostatic sex hormones, adjusting for continuous age at surgery and body mass index (BMI, kg/m²). General linear models estimated geometric means and 95% confidence intervals (95%CIs) of hormones by balding status, chest hair density and Gleason
score (from prostatectomy or biopsy) with adjustment for pre-defined potential confounding variables including age at surgery, study site, race, BMI, education, smoking status, and regular alcohol use. As hormone variables were skewed, natural log transformation was applied to non-missing values, and patients with missing values were dropped from regression models for individual hormone variables. Missing values of potential confounding variables were included in regression models as a separate category. Subgroup analyses were performed by Gleason score (<7 vs ≥7) and race (European American vs African American).

We also conducted two sensitivity analyses: 1) for intraprostatic sex steroid hormones, we used the mean concentrations of two randomly selected tissue pieces to evaluate the robustness of the main results in general linear models, given the potential variation in measurement errors from the use of a variable number of eligible tissue pieces per subject (median = 4); and 2) we alternatively modeled balding status or three-level chest hair density as the outcome and tertiles of each hormone variable as the exposure using binary and ordinal logistic regression, respectively. To assess trends across tertiles, we assigned the median value of each tertile and modeled this as a continuous variable in logistic regressions.

Two-sided P values <0.05 were considered statistically significant. SAS v9.3 (SAS Institute, Inc., Cary, NC) was used for statistical analyses.

3 | RESULTS

Of the 248 patients in this analysis, 144 (58%) presented some degree of baldness and 52 (22%) some degree of dense chest hair (Table 1). Age-adjusted correlation between binary balding status and three-level chest hair density was weak (r = 0.05). Patient characteristics distributed evenly by balding status, while patients with dense chest hair were more likely to be European Americans, have a college degree or higher, and have high-grade prostate cancer. After adjustment for age, differences in these characteristics by chest hair density became minimal (data not tabulated). Supplemental Table S1 shows the distribution of crude concentrations of sex hormones and SHBG. Partial Spearman's correlation coefficients adjusted for age and BMI demonstrated very strong correlations for pairs of testosterone and DHT (r = 0.74), testosterone and SHBG (r = 0.68), testosterone and estradiol (r = 0.53), DHT and SHBG (r = 0.61), and estrone and estradiol (r = 0.66) in serum, as well as estrone and estradiol (r = 0.64) in tissue (data not tabulated).

Geometric means of hormone variables by balding status are shown in Table 2. Bald patients were more likely to have higher serum testosterone, DHT, estrone, estradiol, and SHBG, as well as higher intraprostatic testosterone concentrations with full adjustment for potential confounding variables. Stratified analyses by Gleason score showed that such associations were mainly observed in Gleason score ≥7 prostate cancers, although the multiplicative interaction between balding status and Gleason score for each hormone variable was not statistically significant (Supplemental Table S2). Meanwhile, stratified analyses by race demonstrated that only bald European Americans had statistically significantly higher testosterone, DHT, and SHBG in serum, and estrone, estradiol, and androstenedione/estrone ratio in tissue (Supplemental Table S3). However, associations were in the same direction among African Americans, and multiplicative interactions were null between balding status and race for individual hormone variables. Given androgenic sensitivity differs by scalp region,15 we also presented geometric means by three-level scalp balding category in Supplemental Table S4, despite limited counts for frontal balding only (n = 20). Distributions of hormone variables were similar between frontal balding only and vertex plus frontal balding, although the latter group appeared to have higher androstenedione in serum (P = 0.013).

Sensitivity analyses in which tertiles of each hormone variable were modeled as the exposure, as opposed to the outcome, provided mostly consistent results, except that the association for intraprostatic testosterone concentrations became null and an inverse association for intraprostatic androstenedione/estrone ratio was observed (adjusted P_trend = 0.042, Supplemental Table S5). Increased SHBG appeared to drive the association for testosterone in serum; when we modeled testosterone and SHBG simultaneously, the positive association for testosterone was attenuated to the null (ORthird tertile vs first tertile = 1.62, 95% CI = 0.67-3.91), whereas the positive association for SHBG remained significant (ORthird tertile vs first tertile = 3.00, 95% CI = 1.19-7.53) (data not tabulated). Results were consistent when we simultaneously modeled testosterone and SHBG as continuous variables (P_testosterone = 0.83 and P_SHBG = 0.01). Tentative evidence was found that increased testosterone drove the association for estradiol in serum, as simultaneous adjustment for continuous testosterone and estradiol attenuated the association for estradiol to the null (P_estradiol = 0.197 and P_testosterone = 0.05), but simultaneous adjustment for tertiles of these hormones attenuated the associations to the null for both estradiol (ORthird tertile vs first tertile = 2.16, 95% CI = 0.90-5.20) and testosterone (ORthird tertile vs first tertile = 2.03, 95% CI = 0.90-4.57) (data not tabulated).

Geometric means of hormone variables by chest hair density provided no evidence of an association (Table 3). There was little evidence for effect modification by Gleason score (Supplemental Table S6) or race (Supplemental Table S7). Compared with the main results for chest hair density, modeling tertiles of each hormone variables as the exposure resulted in similarly null associations (Supplemental Table S5).

Sensitivity analyses for intraprostatic sex steroid hormones that used two pieces of randomly selected adjacent normal tissue per subject did not materially alter the results, compared with the main models that used all eligible tissues (data not tabulated).

4 | DISCUSSION

In this study, serum and intraprostatic sex steroid hormones were quantified in relation to male pattern baldness and chest hair density in men diagnosed with localized prostate cancer. We found evidence for strong positive associations of circulating testosterone, DHT, estradiol,
and SHBG with male pattern baldness. However, we found limited evidence for associations between intraprostatic sex hormones and baldness, although the direction of these associations was consistent with what was observed in the serum analyses. Neither circulating nor intraprostatic sex hormones were statistically significantly associated with chest hair density. There was little evidence to suggest that Gleason score or race modified these relationships, although the statistical power for interaction tests may be limited by the modest sample size.

Both the prostate gland and human hair follicles are responsive to sex steroid hormones. Testosterone produced by Leydig cells of the testes is the predominant circulating androgen in men and is

### Table 1

Patient characteristics by balding status and chest hair density (N = 248)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Balding status (n = 248)</th>
<th>Chest hair density (n = 239)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n = 104)</td>
<td>Any (n = 144)</td>
</tr>
<tr>
<td>Age at surgery (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>58.4 (8.1)</td>
<td>60.4 (6.4)</td>
</tr>
<tr>
<td>≤55</td>
<td>37 (35.6%)</td>
<td>32 (22.2%)</td>
</tr>
<tr>
<td>56-60</td>
<td>23 (22.1%)</td>
<td>44 (30.6%)</td>
</tr>
<tr>
<td>61-65</td>
<td>25 (24.0%)</td>
<td>32 (22.2%)</td>
</tr>
<tr>
<td>&gt;65</td>
<td>19 (18.3%)</td>
<td>35 (24.3%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European American</td>
<td>61 (58.7%)</td>
<td>73 (50.7%)</td>
</tr>
<tr>
<td>African American</td>
<td>38 (36.5%)</td>
<td>68 (47.2%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (2.9%)</td>
<td>3 (2.1%)</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than high school</td>
<td>8 (7.7%)</td>
<td>12 (8.3%)</td>
</tr>
<tr>
<td>High school/Technical school</td>
<td>25 (24.0%)</td>
<td>33 (22.9%)</td>
</tr>
<tr>
<td>College or higher</td>
<td>58 (55.8%)</td>
<td>73 (50.7%)</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;7</td>
<td>56 (53.8%)</td>
<td>81 (56.3%)</td>
</tr>
<tr>
<td>≥7</td>
<td>38 (36.5%)</td>
<td>55 (38.2%)</td>
</tr>
<tr>
<td>&gt;7</td>
<td>6 (5.8%)</td>
<td>6 (4.2%)</td>
</tr>
<tr>
<td>Body mass index (BMI, kg/m²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>102</td>
<td>143</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>26.9 (3.3)</td>
<td>28.1 (10.4)</td>
</tr>
<tr>
<td>≤25.0</td>
<td>29 (27.9%)</td>
<td>37 (25.7%)</td>
</tr>
<tr>
<td>25.0-29.9</td>
<td>58 (55.8%)</td>
<td>76 (52.8%)</td>
</tr>
<tr>
<td>≥30.0</td>
<td>17 (16.3%)</td>
<td>31 (21.5%)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>38 (36.5%)</td>
<td>48 (33.3%)</td>
</tr>
<tr>
<td>Former</td>
<td>38 (36.5%)</td>
<td>55 (38.2%)</td>
</tr>
<tr>
<td>Current</td>
<td>12 (11.5%)</td>
<td>8 (5.6%)</td>
</tr>
<tr>
<td>Regular alcohol use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>31 (29.8%)</td>
<td>45 (31.3%)</td>
</tr>
<tr>
<td>Former</td>
<td>11 (10.6%)</td>
<td>25 (17.4%)</td>
</tr>
<tr>
<td>Current</td>
<td>49 (47.1%)</td>
<td>47 (32.6%)</td>
</tr>
</tbody>
</table>

Column percentage does not add up to 100% due to missing data.

*aNine prostate cancer patients were excluded for tabulation of chest hair density due to missing data.

*bP-values were computed by Wilcoxon Rank-sum test for continuous variables and Chi-square/Fisher’s exact test for categorical variables using non-missing values.

*cP-values were calculated for the continuous covariate.

*dP-values were calculated for the categorical covariate.
irreversibly converted to the most potent androgen, DHT, by 5αR in many peripheral tissues, such as the prostate and skin. DHT and, to a lesser extent, testosterone intracellularly bind to AR stimulating downstream androgenic action including hair stimulation and inhibition, as well as prostate growth and carcinogenesis. There are three isoenzymes of 5αR (types I, II, and III). The function of 5αR1 and 5αR2 are consistently related to testosterone metabolism, and are expressed at different body sites and organ compartments. Prostatic epithelium and stroma express higher concentrations of 5αR2, as highlighted by an efficient reduction in intraprostatic DHT through finasteride treatment and by its comparable efficacy to dutasteride (a dual inhibitor for 5αR1 and 5αR2) treatment for benign prostatic hyperplasia. Meanwhile, sebaceous glands predominantly express 5αR1, and scalp hair follicles produce higher levels of 5αR2. Both isoenzymes play critical roles in balding development as supported by the superior efficacy of dutasteride versus finasteride in treating baldness.

### TABLE 2

Geometric means of sex steroid hormones and SHBG by balding status at mean age of 60 years (N = 248)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>Minimally adjusted</th>
<th>Any (n = 144)</th>
<th>P-value</th>
<th>Fully adjusted</th>
<th>Any (n = 144)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum (ng/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>248</td>
<td>420.1 (387.9, 455.0)</td>
<td>481.5 (450.1, 515.1)</td>
<td>0.012</td>
<td>416.4 (384.1, 451.3)</td>
<td>484.6 (452.8, 518.6)</td>
</tr>
<tr>
<td>DHT</td>
<td>248</td>
<td>46.4 (43.0, 50.0)</td>
<td>53.7 (50.4, 57.2)</td>
<td>0.004</td>
<td>45.9 (42.7, 49.4)</td>
<td>54.1 (50.9, 57.5)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>248</td>
<td>507.2 (458.3, 561.2)</td>
<td>492.3 (451.9, 536.3)</td>
<td>0.663</td>
<td>500.3 (451.4, 554.4)</td>
<td>497.2 (456.0, 542.1)</td>
</tr>
<tr>
<td>A</td>
<td>248</td>
<td>67.9 (62.7, 73.4)</td>
<td>70.1 (65.6, 75.0)</td>
<td>0.539</td>
<td>66.9 (61.7, 72.5)</td>
<td>70.9 (66.2, 75.9)</td>
</tr>
<tr>
<td>E1</td>
<td>248</td>
<td>5.0 (4.7, 5.4)</td>
<td>5.6 (5.3, 5.9)</td>
<td>0.030</td>
<td>5.0 (4.7, 5.4)</td>
<td>5.6 (5.3, 5.9)</td>
</tr>
<tr>
<td>E2</td>
<td>248</td>
<td>2.9 (2.7, 3.1)</td>
<td>3.3 (3.1, 3.5)</td>
<td>0.004</td>
<td>2.9 (2.7, 3.1)</td>
<td>3.2 (3.1, 3.4)</td>
</tr>
<tr>
<td>T/E2 ratio</td>
<td>248</td>
<td>147.7 (135.8, 160.6)</td>
<td>147.1 (137.0, 157.9)</td>
<td>0.948</td>
<td>144.9 (134.0, 156.7)</td>
<td>149.1 (139.6, 159.3)</td>
</tr>
<tr>
<td>A/E1 ratio</td>
<td>248</td>
<td>13.5 (12.4, 14.6)</td>
<td>12.6 (11.8, 13.6)</td>
<td>0.242</td>
<td>13.3 (12.3, 14.4)</td>
<td>12.8 (11.9, 13.7)</td>
</tr>
<tr>
<td>SHBG (nmol/L)</td>
<td>248</td>
<td>29.8 (27.7, 32.0)</td>
<td>35.4 (33.3, 37.6)</td>
<td>0.001</td>
<td>29.7 (27.7, 31.9)</td>
<td>35.4 (33.4, 37.6)</td>
</tr>
<tr>
<td>Free T</td>
<td>248</td>
<td>10.7 (9.9, 11.4)</td>
<td>11.4 (10.8, 12.1)</td>
<td>0.140</td>
<td>10.6 (9.8, 11.4)</td>
<td>11.5 (10.8, 12.2)</td>
</tr>
<tr>
<td>Free E2</td>
<td>248</td>
<td>0.08 (0.08, 0.09)</td>
<td>0.09 (0.08, 0.09)</td>
<td>0.064</td>
<td>0.08 (0.08, 0.09)</td>
<td>0.09 (0.08, 0.09)</td>
</tr>
</tbody>
</table>

A, androstenedione; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin; T, testosterone; 3α-diol-G, 3α-androstanediol glucuronide.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (five sites, not listed here), BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown), and regular alcohol use (never, former, current, unknown).

*P*-values were calculated for a global test of differences in geometric means.

A direct comparison of results from epidemiological studies on circulating sex hormones in relation to male pattern baldness is challenging given differences in age, race, laboratory assays (eg, RIA, mass spectrometry, electrochemiluminescence immunoassay), health status (with/without malignancy/other metabolic diseases), and balding categories. Several small studies (n = 6) have assessed this relationship among apparently healthy younger (<45 years old) men and found conflicting associations; some reported that bald men were more likely to have increased testosterone, increased testosterone/SHBG ratio, increased DHT and decreased SHBG levels, whereas others have reported either null or opposing findings. On the other hand, a cross-sectional study among older (>65 years) healthy Greek men specifically compared vertex balding to those without (ie, no/minimal plus frontal balding. The predominant form expressed in chest skin, however, chest hair follicles have been suggested to be less androgen-dependent, and this is in line with the null association of chest hair density with sex steroid hormones in this analysis, albeit two prior observational studies have reported otherwise.
<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>N</th>
<th>Minimally adjusted</th>
<th>Fully adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>None/Sparse (n = 110)</td>
<td>Moderate (n = 77)</td>
</tr>
<tr>
<td>Serum (ng/dL)</td>
<td></td>
<td>239</td>
<td>472.8 (436.1, 512.6)</td>
</tr>
<tr>
<td>T</td>
<td></td>
<td>239</td>
<td>523 (484.6, 56.5)</td>
</tr>
<tr>
<td>DHT</td>
<td></td>
<td>239</td>
<td>4703 (425.7, 519.5)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td></td>
<td>239</td>
<td>69.7 (64.3, 75.5)</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td>239</td>
<td>5.0 (4.7, 5.4)</td>
</tr>
<tr>
<td>E1</td>
<td></td>
<td>239</td>
<td>3.0 (2.8, 3.3)</td>
</tr>
<tr>
<td>E2</td>
<td></td>
<td>239</td>
<td>69.7 (64.3, 75.5)</td>
</tr>
<tr>
<td>T/E2 ratio</td>
<td></td>
<td>239</td>
<td>1601 (147.2, 174.2)</td>
</tr>
<tr>
<td>A/E1 ratio</td>
<td></td>
<td>239</td>
<td>13.8 (12.7, 15.0)</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td></td>
<td>239</td>
<td>34.9 (32.4, 37.6)</td>
</tr>
<tr>
<td>T/E2 ratio</td>
<td></td>
<td>239</td>
<td>1601 (147.2, 174.2)</td>
</tr>
<tr>
<td>T/E2 ratio</td>
<td></td>
<td>239</td>
<td>1601 (147.2, 174.2)</td>
</tr>
<tr>
<td>Adjacent normal prostate tissue (pg/g W)</td>
<td></td>
<td>236</td>
<td>222.2 (204.0, 241.9)</td>
</tr>
<tr>
<td>T</td>
<td></td>
<td>239</td>
<td>679.1 (6403.8, 7155.3)</td>
</tr>
<tr>
<td>DHT</td>
<td></td>
<td>236</td>
<td>2625.3 (2425.9, 2837.3)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td></td>
<td>223</td>
<td>65.8 (60.2, 71.9)</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td>223</td>
<td>45.2 (41.1, 49.7)</td>
</tr>
<tr>
<td>E2</td>
<td></td>
<td>213</td>
<td>8.9 (8.0, 10.0)</td>
</tr>
</tbody>
</table>

A, androstenedione; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin; T, testosterone; 3α-diol-G, 3α-androstanediol glucuronide.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here).

*Additionally adjusted for BMI (<25.0, 25.0-29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown), and regular alcohol use (never, former, current, unknown).

*P-values were calculated for a global test of differences in geometric means.
only) and did not find associations for serum testosterone, estradiol, DHEA-S, or SHBG. Furthermore, another study in the US among 268 prostate cancer cases and controls found that men with vertex balding had higher serum age- and race-adjusted free testosterone levels than those who had little or no hair loss.\(^47\)

This study supports associations of circulating sex hormones with male pattern baldness in an older prostate cancer population. However, comparisons between our results with previously published studies requires caution. First, there is evidence that the presence of prostate cancer may slightly suppress circulating testosterone concentrations through the hypothalamic-pituitary axis.\(^48\)–\(^51\) Thus, associations observed in this case series may differ from what may be expected in a healthy population. Second, our analytical sample is older, compared to most prior studies, with a mean age of 60 years. It is known that circulating testosterone decreases,\(^52\)–\(^54\) while male pattern baldness progresses with advancing age.\(^55\) However, we would expect minimal confounding by age in this study because distributions of age were not statistically significantly different by balding status and we adjusted for age in regression models.

Given the strong parallels in androgen dependency and in age-related changes between scalp hair follicles and the prostate, we speculated that male pattern baldness might serve as a proxy for intrinsic enhanced androgenic action in androgen-responsive organs. Such enhanced androgenic action may be partly explained by genetic susceptibility, particularly within the AR signaling pathway. For example, genetic variation in AR gene on the X-chromosome has commonly been associated with male pattern baldness in European descendants.\(^56\)–\(^58\) Meanwhile, genes involved in androgen biosynthesis and metabolism, as well as AR have been associated with prostate cancer risk.\(^59\)–\(^61\) Despite these shared etiological factors, we did not find robust associations between intraprostatic sex steroid hormones and male pattern baldness, although associations were directionally consistent with our hypothesis. This implies that sex steroid hormone-related factors (eg, AR), rather than the sex steroids hormones themselves, play important roles in organ-specific androgenic actions, and that other overlapping pathways may be involved in associations between these two complex conditions. Although the directional consistency could be explained by the field effect of hormonal carcinogenesis on histologically normal tissue and/or a product of reverse causation from the adjacent cancerous foci—as supported by significantly elevated levels of testosterone, DHT, and estradiol in normal tissue adjacent to Gleason ≥7 tumor foci versus Gleason <7 foci (Supplemental Table S1)—we did not find evidence that Gleason score modified the association between intraprostatic sex hormones and balding status (Supplemental Table S3).

Strengths of this study include central review by an experienced genitourinary pathologist, nurse-assessed dermatological characteristics, and simultaneous measurement of circulating and intraprostatic sex steroid hormones. Limitations include the fact that both circulating and intraprostatic sex hormones were only measured once and, therefore, intra-individual temporal variations could not be assessed. Meanwhile, male pattern baldness at older age may reflect cumulative exposure to circulating sex steroid hormones as opposed to the single time-point we have assessed in serum and tissue at the age of prostate cancer diagnosis (mean = 60, range = 37–86 years), and this mismatched time-window of sex hormone exposure may have reduced statistical power. Second, we combined hair-loss patterns because the number of frontal balding only was relatively small. Although we were unable to specify whether observed associations were modified by hair-loss patterns, the misclassification of balding status was minimized.

In conclusion, this study provides evidence that elevated circulating testosterone, DHT, estradiol, and SHBG are associated with balding status in prostate cancer cases. Male balding serves as a proxy for circulating sex hormone concentrations and may explain prior studies showing an association between male pattern baldness and prostate cancer incidence and specific mortality. Testosterone is the only elevated intraprostatic sex hormone in men with balding; lack of an association between balding and other intraprostatic sex hormones reaffirms differences in organ-specific sex steroid hormone metabolism and cellular response.

**ACKNOWLEDGMENTS**

The authors thank Dr. Ruth M. Pfeiffer at Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute for her statistical consultation support. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported by the Intramural Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, United States Department of Health & Human Services.

**CONFLICTS OF INTEREST**

The authors declare that there is no conflict of interest.

**ORCID**

Cindy Ke Zhou \(\text{http://orcid.org/0000-0003-4814-4305}\)

**REFERENCES**


12. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol. 1992;133:141–147.


SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.
Supplemental Table and Figure Legends:

Supplemental Table 1. Distribution of sex steroid hormones and SHBG overall and their geometric means by Gleason score (N=248)

Supplemental Table 2. Adjusted geometric means of sex steroid hormones and SHBG by balding status and Gleason score (N=242)

Supplemental Table 3. Adjusted geometric means of sex steroid hormones and SHBG by balding status and race (N=240)

Supplemental Table 4. Geometric means of sex steroid hormones and SHBG by three-level balding category (N=248)

Supplemental Table 5. Adjusted odds ratios (ORs) and 95% confidence intervals (95%CIs) for tertiles of sex hormones and SHBG using binary logistic regression with balding status as the outcome variable or using ordinal logistic regression with chest hair density as the outcome variable

Supplemental Table 6. Adjusted geometric means of sex steroid hormones and SHBG by chest hair density and Gleason score (N=234)

Supplemental Table 7. Adjusted geometric means of sex steroid hormones and SHBG by chest hair density and race (N=231)

Supplemental Fig 1. Modified Norwood-Hamilton Scale used to score hair loss patterns in NCI Prostate Tissue Study
Supplemental Table 1. Distribution of sex steroid hormones and SHBG overall and their geometric means by Gleason score (N=248)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>N</th>
<th>Lower quartile</th>
<th>Median</th>
<th>Upper quartile</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Geometric means*</th>
<th>Geometric means*</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum (ng/dl)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>24</td>
<td>343.9</td>
<td>473.5</td>
<td>620.2</td>
<td>34.0</td>
<td>1439.6</td>
<td>443.3 (413.2, 475.7)</td>
<td>443.3 (413.2, 475.7)</td>
<td>0.302</td>
</tr>
<tr>
<td>DHT</td>
<td>24</td>
<td>38.8</td>
<td>50.4</td>
<td>67.2</td>
<td>6.6</td>
<td>189.9</td>
<td>50.3 (47.2, 53.7)</td>
<td>51.1 (47.4, 55.0)</td>
<td>0.769</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>24</td>
<td>369.0</td>
<td>505.0</td>
<td>720.0</td>
<td>104.0</td>
<td>1892.0</td>
<td>502.1 (459.9, 548.3)</td>
<td>504.0 (455.5, 557.6)</td>
<td>0.958</td>
</tr>
<tr>
<td>A</td>
<td>24</td>
<td>52.2</td>
<td>69.5</td>
<td>90.8</td>
<td>24.4</td>
<td>294.4</td>
<td>70.1 (65.4, 75.3)</td>
<td>68.3 (63.0, 74.1)</td>
<td>0.637</td>
</tr>
<tr>
<td>E1</td>
<td>24</td>
<td>4.3</td>
<td>5.5</td>
<td>6.8</td>
<td>1.2</td>
<td>17.4</td>
<td>5.3 (5.0, 5.6)</td>
<td>5.3 (5.0, 5.7)</td>
<td>0.984</td>
</tr>
<tr>
<td>E2</td>
<td>24</td>
<td>2.4</td>
<td>3.2</td>
<td>4.1</td>
<td>0.7</td>
<td>9.2</td>
<td>3.0 (2.8, 3.2)</td>
<td>3.2 (3.0, 3.4)</td>
<td>0.209</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>24</td>
<td>113.3</td>
<td>147.8</td>
<td>196.0</td>
<td>23.8</td>
<td>728.2</td>
<td>147.5 (137.9, 158.0)</td>
<td>147.1 (135.0, 159.1)</td>
<td>0.952</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>24</td>
<td>9.5</td>
<td>12.3</td>
<td>17.5</td>
<td>4.7</td>
<td>83.3</td>
<td>13.2 (12.3, 14.2)</td>
<td>12.9 (11.9, 14.0)</td>
<td>0.652</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>24</td>
<td>26.1</td>
<td>33.1</td>
<td>41.9</td>
<td>10.4</td>
<td>129.0</td>
<td>32.3 (30.4, 34.4)</td>
<td>33.0 (30.7, 35.5)</td>
<td>0.680</td>
</tr>
<tr>
<td>Free T</td>
<td>24</td>
<td>8.9</td>
<td>11.7</td>
<td>14.2</td>
<td>0.7</td>
<td>23.9</td>
<td>10.9 (10.3, 11.6)</td>
<td>11.5 (10.7, 12.3)</td>
<td>0.304</td>
</tr>
<tr>
<td>Free E2</td>
<td>24</td>
<td>0.07</td>
<td>0.09</td>
<td>0.11</td>
<td>0.02</td>
<td>0.23</td>
<td>0.08 (0.08, 0.09)</td>
<td>0.09 (0.08, 0.09)</td>
<td>0.240</td>
</tr>
<tr>
<td><strong>Adjacent normal prostate tissue (pg/g W)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>24</td>
<td>165.1</td>
<td>215.0</td>
<td>291.1</td>
<td>64.2</td>
<td>1212.6</td>
<td>209.4 (194.1, 226.0)</td>
<td>238.7 (218.3, 260.9)</td>
<td>0.034</td>
</tr>
<tr>
<td>DHT</td>
<td>24</td>
<td>518.2</td>
<td>6813.1</td>
<td>8061.6</td>
<td>2149.9</td>
<td>21426.2</td>
<td>6304.0 (6008.5, 6614.0)</td>
<td>6982.8 (6607.4, 7379.5)</td>
<td>0.008</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>24</td>
<td>1914.6</td>
<td>2713.5</td>
<td>3572.5</td>
<td>1020.8</td>
<td>7756.2</td>
<td>2583.3 (2412.4, 2766.3)</td>
<td>2819.2 (2605.1, 3050.9)</td>
<td>0.111</td>
</tr>
<tr>
<td>A</td>
<td>22</td>
<td>420.6</td>
<td>583.0</td>
<td>817.4</td>
<td>109.5</td>
<td>2772.2</td>
<td>560.6 (514.9, 610.4)</td>
<td>619.6 (560.9, 684.4)</td>
<td>0.144</td>
</tr>
<tr>
<td>E1</td>
<td>23</td>
<td>526</td>
<td>72.4</td>
<td>98.9</td>
<td>18.2</td>
<td>244.2</td>
<td>71.0 (65.8, 76.5)</td>
<td>74.4 (68.2, 81.2)</td>
<td>0.432</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>35.2</td>
<td>47.2</td>
<td>65.6</td>
<td>12.5</td>
<td>223.0</td>
<td>45.7 (42.0, 49.7)</td>
<td>52.3 (47.4, 57.7)</td>
<td>0.048</td>
</tr>
<tr>
<td>--------</td>
<td>----</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-------</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>23</td>
<td>3.3</td>
<td>4.3</td>
<td>5.8</td>
<td>1.1</td>
<td>16.6</td>
<td>4.4 (4.1, 4.8)</td>
<td>4.5 (4.1, 4.9)</td>
<td>0.948</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>22</td>
<td>5.4</td>
<td>8.3</td>
<td>12.1</td>
<td>2.2</td>
<td>45.5</td>
<td>8.0 (7.2, 8.8)</td>
<td>8.4 (7.5, 9.5)</td>
<td>0.494</td>
</tr>
</tbody>
</table>

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstenediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here), BMI (<25.0, 25.5–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown), and regular alcohol use (never, former, current, unknown).

*P*-values were calculated for a global test of differences in geometric means.
### Supplemental Table 2. Adjusted geometric means of sex steroid hormones and SHBG by balding status and Gleason score (N=242)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>Serum (ng/dl)</th>
<th>N</th>
<th>No balding (n=105)</th>
<th>Any balding (n=105)</th>
<th>P-value</th>
<th>N</th>
<th>No balding (n=105)</th>
<th>Any balding (n=105)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>427.3 (381.0, 479.1)</td>
<td>137</td>
<td>461.0 (426.1, 514.1)</td>
<td>105</td>
<td>411.0 (366.0, 461.5)</td>
<td>0.244</td>
<td>105</td>
<td>497.9 (451.9, 548.6)</td>
<td>0.018</td>
</tr>
<tr>
<td>DHT</td>
<td>48.3 (43.6, 53.4)</td>
<td>137</td>
<td>52.9 (48.7, 57.4)</td>
<td>0.182</td>
<td>105</td>
<td>44.5 (39.7, 50.0)</td>
<td>0.348</td>
<td>105</td>
<td>49.9 (43.8, 56.4)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>540.0 (486.6, 622.2)</td>
<td>137</td>
<td>503.5 (448.3, 565.5)</td>
<td>0.069</td>
<td>105</td>
<td>482.0 (410.3, 566.1)</td>
<td>0.251</td>
<td>105</td>
<td>485.1 (434.1, 554.9)</td>
</tr>
<tr>
<td>A</td>
<td>71.9 (64.0, 80.8)</td>
<td>137</td>
<td>71.1 (64.6, 78.2)</td>
<td>0.876</td>
<td>105</td>
<td>62.8 (55.4, 71.1)</td>
<td>0.223</td>
<td>105</td>
<td>69.7 (62.8, 77.4)</td>
</tr>
<tr>
<td>E1</td>
<td>5.3 (4.0, 5.9)</td>
<td>137</td>
<td>5.6 (5.2, 6.1)</td>
<td>0.037</td>
<td>105</td>
<td>4.6 (4.2, 5.1)</td>
<td>0.013</td>
<td>105</td>
<td>5.4 (5.0, 5.8)</td>
</tr>
<tr>
<td>E2</td>
<td>3.1 (2.8, 3.4)</td>
<td>137</td>
<td>3.2 (2.9, 3.4)</td>
<td>0.029</td>
<td>105</td>
<td>2.6 (2.4, 2.9)</td>
<td>0.004</td>
<td>105</td>
<td>3.4 (3.1, 3.7)</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>138.6 (124.8, 153.8)</td>
<td>137</td>
<td>148.2 (136.1, 161.4)</td>
<td>0.023</td>
<td>105</td>
<td>157.0 (138.0, 178.8)</td>
<td>0.403</td>
<td>105</td>
<td>147.9 (132.8, 164.9)</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>13.5 (12.1, 15.2)</td>
<td>137</td>
<td>12.6 (11.1, 13.8)</td>
<td>0.363</td>
<td>105</td>
<td>13.6 (11.0, 15.5)</td>
<td>0.054</td>
<td>105</td>
<td>12.9 (11.5, 14.4)</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>29.1 (26.4, 32.1)</td>
<td>137</td>
<td>34.6 (32.2, 37.7)</td>
<td>0.008</td>
<td>105</td>
<td>30.3 (27.0, 34.0)</td>
<td>0.079</td>
<td>105</td>
<td>34.9 (31.7, 38.5)</td>
</tr>
<tr>
<td>Free T</td>
<td>11.0 (10.0, 12.1)</td>
<td>137</td>
<td>11.2 (10.3, 12.1)</td>
<td>0.771</td>
<td>105</td>
<td>10.3 (9.3, 11.4)</td>
<td>0.045</td>
<td>105</td>
<td>11.9 (10.9, 13.0)</td>
</tr>
<tr>
<td>Free E2</td>
<td>0.09 (0.08, 0.10)</td>
<td>137</td>
<td>0.09 (0.08, 0.09)</td>
<td>0.700</td>
<td>105</td>
<td>0.07 (0.07, 0.08)</td>
<td>0.005</td>
<td>105</td>
<td>0.09 (0.08, 0.10)</td>
</tr>
</tbody>
</table>

### Adjacent normal prostate tissue (pg/g W)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>N</th>
<th>No balding (n=105)</th>
<th>Any balding (n=105)</th>
<th>P-value</th>
<th>N</th>
<th>No balding (n=105)</th>
<th>Any balding (n=105)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>196.1 (174.9, 219.9)</td>
<td>137</td>
<td>228.0 (207.6, 250.5)</td>
<td>0.655</td>
<td>102</td>
<td>214.8 (182.9, 252.3)</td>
<td>0.671</td>
<td>102</td>
</tr>
<tr>
<td>DHT</td>
<td>642.2 (592.3, 696.3)</td>
<td>137</td>
<td>638.3 (592.4, 676.3)</td>
<td>0.792</td>
<td>105</td>
<td>649.0 (599.1, 706.1)</td>
<td>0.719</td>
<td>105</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>2528.0 (2262.3, 2824.8)</td>
<td>136</td>
<td>2687.5 (2379.9, 2856.9)</td>
<td>0.198</td>
<td>103</td>
<td>2699.1 (2365.4, 3079.9)</td>
<td>0.207</td>
<td>103</td>
</tr>
<tr>
<td>A</td>
<td>550.5 (513.9, 655.7)</td>
<td>127</td>
<td>557.0 (503.9, 615.7)</td>
<td>0.166</td>
<td>96</td>
<td>624.8 (521.8, 748.0)</td>
<td>0.634</td>
<td>96</td>
</tr>
<tr>
<td>E1</td>
<td>68.9 (61.2, 77.5)</td>
<td>129</td>
<td>76.1 (69.1, 83.8)</td>
<td>0.211</td>
<td>87</td>
<td>64.2 (55.6, 73.9)</td>
<td>0.080</td>
<td>87</td>
</tr>
<tr>
<td>E2</td>
<td>46.6 (40.8, 53.2)</td>
<td>129</td>
<td>47.3 (42.4, 52.7)</td>
<td>0.074</td>
<td>97</td>
<td>43.1 (36.7, 50.6)</td>
<td>0.014</td>
<td>97</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>4.1 (3.7, 4.7)</td>
<td>129</td>
<td>4.6 (4.2, 5.1)</td>
<td>0.188</td>
<td>97</td>
<td>4.9 (4.1, 5.7)</td>
<td>0.169</td>
<td>97</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>8.6 (7.4, 10.0)</td>
<td>123</td>
<td>7.3 (6.5, 8.3)</td>
<td>0.116</td>
<td>91</td>
<td>7.9 (6.3, 11.7)</td>
<td>0.063</td>
<td>91</td>
</tr>
</tbody>
</table>

**Abbreviations:** T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstanediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here), BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

*P*-values were calculated for a global test of differences in geometric means.

*P*-values were calculated for the multiplicative interaction between balding status and Gleason score.
### Supplemental Table 3. Adjusted geometric means of sex steroid hormones and SHBG by balding status and race (N=240)

<table>
<thead>
<tr>
<th>Sex Hormones</th>
<th>European American (N=134)</th>
<th></th>
<th>African American (N=106)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>No balding</td>
<td>Any balding</td>
<td>P-value*</td>
</tr>
<tr>
<td>T (ng/dl)</td>
<td>134</td>
<td>387.2 (349.3, 429.2)</td>
<td>489.1 (408.0, 493.2)</td>
<td>0.043</td>
</tr>
<tr>
<td>DHT</td>
<td>134</td>
<td>417.7 (37.3, 45.8)</td>
<td>491.1 (45.3, 53.5)</td>
<td>0.015</td>
</tr>
<tr>
<td>3a-diol-G</td>
<td>134</td>
<td>455.3 (394.5, 525.9)</td>
<td>501.7 (440.3, 571.7)</td>
<td>0.342</td>
</tr>
<tr>
<td>A</td>
<td>134</td>
<td>66.7 (58.8, 74.4)</td>
<td>73.4 (66.5, 81.1)</td>
<td>0.213</td>
</tr>
<tr>
<td>E1</td>
<td>134</td>
<td>4.6 (4.2, 4.9)</td>
<td>5.0 (4.6, 5.4)</td>
<td>0.09</td>
</tr>
<tr>
<td>E2</td>
<td>134</td>
<td>2.5 (2.3, 2.8)</td>
<td>2.6 (2.6, 3.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>134</td>
<td>152.8 (138.0, 159.2)</td>
<td>157.7 (143.8, 173.0)</td>
<td>0.659</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>134</td>
<td>14.7 (13.2, 16.5)</td>
<td>14.7 (13.2, 16.2)</td>
<td>0.592</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>134</td>
<td>28.1 (25.7, 30.6)</td>
<td>34.3 (31.7, 37.1)</td>
<td>0.001</td>
</tr>
<tr>
<td>Free T</td>
<td>134</td>
<td>10.0 (9.1, 10.9)</td>
<td>10.8 (9.9, 11.7)</td>
<td>0.224</td>
</tr>
<tr>
<td>Free E2</td>
<td>134</td>
<td>0.07 (0.07, 0.08)</td>
<td>0.08 (0.07, 0.08)</td>
<td>0.322</td>
</tr>
</tbody>
</table>

### Adjacent normal prostate tissue (pg/g W)

<table>
<thead>
<tr>
<th>Sex Hormones</th>
<th>European American (N=132)</th>
<th></th>
<th>African American (N=105)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>No balding</td>
<td>Any balding</td>
<td>P-value*</td>
</tr>
<tr>
<td>T (ng/dl)</td>
<td>132</td>
<td>200.8 (179.3, 224.9)</td>
<td>229.6 (207.6, 254.0)</td>
<td>0.091</td>
</tr>
<tr>
<td>DHT</td>
<td>134</td>
<td>647.1 (566.6, 703.6)</td>
<td>653.1 (586.5, 703.1)</td>
<td>0.581</td>
</tr>
<tr>
<td>3a-diol-G</td>
<td>131</td>
<td>2513.9 (2253.6, 2846.5)</td>
<td>2825.3 (2538.2, 3147.0)</td>
<td>0.107</td>
</tr>
<tr>
<td>A</td>
<td>123</td>
<td>588.7 (513.4, 675.1)</td>
<td>573.3 (508.2, 645.4)</td>
<td>0.776</td>
</tr>
<tr>
<td>E1</td>
<td>128</td>
<td>60.8 (55.4, 67.4)</td>
<td>71.9 (65.3, 78.2)</td>
<td>0.023</td>
</tr>
<tr>
<td>E2</td>
<td>128</td>
<td>41.8 (37.1, 47.0)</td>
<td>50.3 (45.3, 55.8)</td>
<td>0.025</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>128</td>
<td>4.7 (4.2, 5.3)</td>
<td>4.5 (4.0, 4.9)</td>
<td>0.438</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>120</td>
<td>9.9 (8.6, 11.5)</td>
<td>8.0 (7.1, 9.1)</td>
<td>0.030</td>
</tr>
</tbody>
</table>

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3a-diol-G, 3a-androstanediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), study site (5 sites, not listed here), BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

*P-values were calculated for a global test of differences in geometric means.

*P-values were calculated for the multiplicative interaction between balding status and race (European American vs. African American).
Supplemental Table 4. Geometric means of sex steroid hormones and SHBG by three-level balding category (N=248)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>Minimally Adjusted</th>
<th>Fully Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>P-value</td>
</tr>
<tr>
<td>Serum (ng/dl)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No (n=104)</td>
<td>Frontal only</td>
</tr>
<tr>
<td>T</td>
<td>248</td>
<td>420.0</td>
</tr>
<tr>
<td></td>
<td>(387.7, 403.5)</td>
<td>(447.2, 515.8)</td>
</tr>
<tr>
<td>DHT</td>
<td>248</td>
<td>48.4</td>
</tr>
<tr>
<td></td>
<td>(43.6, 50.6)</td>
<td>(50.2, 57.5)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>243</td>
<td>505.9</td>
</tr>
<tr>
<td></td>
<td>(457.2, 512.4)</td>
<td>(419.2, 573.5)</td>
</tr>
<tr>
<td>A</td>
<td>248</td>
<td>68.8</td>
</tr>
<tr>
<td></td>
<td>(63, 78)</td>
<td>(46.6, 67.8)</td>
</tr>
<tr>
<td>E1</td>
<td>248</td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td>(4.7, 5.4)</td>
<td>(4.2, 5.8)</td>
</tr>
<tr>
<td>E2</td>
<td>248</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>(2.7, 3.1)</td>
<td>(2.6, 3.6)</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>248</td>
<td>147.5</td>
</tr>
<tr>
<td></td>
<td>(135.8, 129.5)</td>
<td>(135.9, 157.1)</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>248</td>
<td>13.5</td>
</tr>
<tr>
<td></td>
<td>(12.4, 14.7)</td>
<td>(9.4, 13.7)</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>248</td>
<td>29.8</td>
</tr>
<tr>
<td></td>
<td>(27.7, 32)</td>
<td>(30.9, 43.3)</td>
</tr>
<tr>
<td>Free T</td>
<td>248</td>
<td>12.6</td>
</tr>
<tr>
<td></td>
<td>(9.9, 11.4)</td>
<td>(9.7, 12.5)</td>
</tr>
<tr>
<td>Free E2</td>
<td>248</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>(0.08, 0.09)</td>
<td>(0.07, 0.10)</td>
</tr>
<tr>
<td>Adjacent normal prostate tissue (mg/g W)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>245</td>
<td>205.8</td>
</tr>
<tr>
<td></td>
<td>(188.4, 199.5)</td>
<td>(238, 254)</td>
</tr>
<tr>
<td>DHT</td>
<td>248</td>
<td>644.0</td>
</tr>
<tr>
<td></td>
<td>(609, 520)</td>
<td>(543, 618)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>244</td>
<td>2590.9</td>
</tr>
<tr>
<td></td>
<td>(2247, 2917)</td>
<td>(2697, 2993)</td>
</tr>
<tr>
<td>A</td>
<td>229</td>
<td>588.2</td>
</tr>
<tr>
<td></td>
<td>(533.5, 612)</td>
<td>(577, 599)</td>
</tr>
<tr>
<td>E1</td>
<td>232</td>
<td>655.6</td>
</tr>
<tr>
<td></td>
<td>(595, 710)</td>
<td>(702, 817)</td>
</tr>
<tr>
<td>Adjacent normal prostate tissue (mg/g W)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>245</td>
<td>205.8</td>
</tr>
<tr>
<td></td>
<td>(188.4, 199.5)</td>
<td>(238, 254)</td>
</tr>
<tr>
<td>DHT</td>
<td>248</td>
<td>644.0</td>
</tr>
<tr>
<td></td>
<td>(609, 520)</td>
<td>(543, 618)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>244</td>
<td>2590.9</td>
</tr>
<tr>
<td></td>
<td>(2247, 2917)</td>
<td>(2697, 2993)</td>
</tr>
<tr>
<td>A</td>
<td>229</td>
<td>588.2</td>
</tr>
<tr>
<td></td>
<td>(533.5, 612)</td>
<td>(577, 599)</td>
</tr>
<tr>
<td>E1</td>
<td>232</td>
<td>655.6</td>
</tr>
<tr>
<td></td>
<td>E2</td>
<td>T/E2 Ratio</td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>44.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(40.3, 49.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(48.5, 57.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(40.7, 49.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>44.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(47.5, 56.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(0.75, 0.80)</td>
</tr>
<tr>
<td></td>
<td>232</td>
<td>232</td>
</tr>
<tr>
<td></td>
<td>4.6</td>
<td>4.6</td>
</tr>
<tr>
<td></td>
<td>(4.1, 5.0)</td>
<td>(3.7, 5.7)</td>
</tr>
<tr>
<td></td>
<td>4.6</td>
<td>4.3</td>
</tr>
<tr>
<td></td>
<td>(4.0, 4.7)</td>
<td>(4.0, 4.7)</td>
</tr>
<tr>
<td></td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>(0.4, 0.9)</td>
<td>(0.4, 0.9)</td>
</tr>
<tr>
<td></td>
<td>0.57</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>(0.2, 0.5)</td>
<td>(0.2, 0.5)</td>
</tr>
<tr>
<td></td>
<td>4.5</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>(3.5, 4.5)</td>
<td>(3.5, 4.5)</td>
</tr>
<tr>
<td></td>
<td>4.7</td>
<td>8.1</td>
</tr>
<tr>
<td></td>
<td>(3.5, 5.7)</td>
<td>(3.5, 5.7)</td>
</tr>
<tr>
<td></td>
<td>4.4</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>(3.4, 5.4)</td>
<td>(3.4, 5.4)</td>
</tr>
<tr>
<td></td>
<td>0.80</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>(0.5, 0.9)</td>
<td>(0.5, 0.9)</td>
</tr>
</tbody>
</table>

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstanediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here).

*Additionally adjusted for BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

*P-values were calculated for a global test of differences in geometric means.

*P-values were calculated for differences in geometric means comparing vertex + frontal with frontal only.
Supplemental Table 5. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for tertiles of sex hormones and SHBG using binary logistic regression with balding status as the outcome variable or using ordinal logistic regression with chest hair density as the outcome variable.

<table>
<thead>
<tr>
<th>Sex hormones Serum (ng/dl)</th>
<th>Balding status (N=248)</th>
<th>Chest hair density (N=239)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>An</td>
</tr>
<tr>
<td>T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;387.0</td>
<td>44</td>
<td>38</td>
</tr>
<tr>
<td>387.0-550.9</td>
<td>36</td>
<td>48</td>
</tr>
<tr>
<td>≥551.0</td>
<td>24</td>
<td>58</td>
</tr>
<tr>
<td>P-trend†</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>DHT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;44.0</td>
<td>48</td>
<td>35</td>
</tr>
<tr>
<td>44.0-60.4</td>
<td>29</td>
<td>54</td>
</tr>
<tr>
<td>≥60.5</td>
<td>27</td>
<td>55</td>
</tr>
<tr>
<td>P-trend†</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;410.0</td>
<td>32</td>
<td>51</td>
</tr>
<tr>
<td>410.0-622.9</td>
<td>35</td>
<td>47</td>
</tr>
<tr>
<td>≥623.0</td>
<td>37</td>
<td>46</td>
</tr>
<tr>
<td>P-trend†</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;58.4</td>
<td>33</td>
<td>50</td>
</tr>
<tr>
<td>58.4-83.6</td>
<td>38</td>
<td>45</td>
</tr>
<tr>
<td>≥83.7</td>
<td>33</td>
<td>49</td>
</tr>
<tr>
<td>P-trend†</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>E1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;4.6</td>
<td>39</td>
<td>40</td>
</tr>
<tr>
<td>4.6-6.3</td>
<td>41</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>2.09 (1.00, 4.39)</td>
<td>2.21 (0.99, 4.96)</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>P-trend</td>
<td>0.046</td>
<td>0.051</td>
</tr>
<tr>
<td>T/E2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2.7</td>
<td>1.00 (referent)</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td>2.7-3.7</td>
<td>2.56 (1.31, 5.07)</td>
<td>2.70 (1.33, 5.50)</td>
</tr>
<tr>
<td>≥3.8</td>
<td>2.74 (1.29, 5.83)</td>
<td>2.94 (1.33, 6.51)</td>
</tr>
<tr>
<td>P-trend</td>
<td>4.18 (1.14, 2.19)</td>
<td></td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;124.9</td>
<td>1.00 (referent)</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td>124.9-180.8</td>
<td>0.87 (0.46, 1.66)</td>
<td>0.96 (0.48, 1.90)</td>
</tr>
<tr>
<td>≥180.9</td>
<td>0.98 (0.50, 1.91)</td>
<td>1.13 (0.55, 2.36)</td>
</tr>
<tr>
<td>P-trend</td>
<td>0.017</td>
<td>0.056</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10.3</td>
<td>1.00 (referent)</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td>10.3-15.3</td>
<td>0.65 (0.33, 1.26)</td>
<td>0.66 (0.33, 1.34)</td>
</tr>
<tr>
<td>≥15.4</td>
<td>0.88 (0.44, 1.76)</td>
<td>0.99 (0.47, 2.08)</td>
</tr>
<tr>
<td>P-trend</td>
<td>0.328</td>
<td>0.391</td>
</tr>
<tr>
<td>SHBG (nmol/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;28.0</td>
<td>1.00 (referent)</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td>28.0-39.4</td>
<td>1.26 (0.67, 2.39)</td>
<td>1.22 (0.62, 2.40)</td>
</tr>
<tr>
<td>≥39.5</td>
<td>3.49 (1.69, 7.24)</td>
<td>3.81 (1.75, 8.31)</td>
</tr>
<tr>
<td>P-trend</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Free T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;9.9</td>
<td>1.00 (referent)</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td>9.9-13.1</td>
<td>1.08 (0.57, 2.04)</td>
<td>1.25 (0.64, 2.45)</td>
</tr>
<tr>
<td>≥13.2</td>
<td>2.08 (1.06, 4.11)</td>
<td>2.53 (1.23, 5.23)</td>
</tr>
<tr>
<td></td>
<td>$P$-trend$^a$</td>
<td>10</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------</td>
<td>----</td>
</tr>
<tr>
<td><strong>Free E2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;0.074$</td>
<td>43</td>
<td>39</td>
</tr>
<tr>
<td>$0.074 - 0.103$</td>
<td>30</td>
<td>53</td>
</tr>
<tr>
<td>$\geq 0.104$</td>
<td>31</td>
<td>52</td>
</tr>
<tr>
<td><strong>Adjacent normal prostate tissue (pg/g W)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>T</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;181.8$</td>
<td>32</td>
<td>49</td>
</tr>
<tr>
<td>$181.8 - 255.4$</td>
<td>39</td>
<td>44</td>
</tr>
<tr>
<td>255.4</td>
<td>30</td>
<td>51</td>
</tr>
<tr>
<td>$\geq 255.5$</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td><strong>DHT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;6065.5$</td>
<td>39</td>
<td>44</td>
</tr>
<tr>
<td>$6065.5 - 7492.6$</td>
<td>33</td>
<td>49</td>
</tr>
<tr>
<td>7492.6</td>
<td>32</td>
<td>51</td>
</tr>
<tr>
<td>$\geq 7492.7$</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td><strong>3α-diol-G</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;2254.2$</td>
<td>37</td>
<td>44</td>
</tr>
<tr>
<td>$2254.2 - 3198.8$</td>
<td>33</td>
<td>48</td>
</tr>
<tr>
<td>3198.8</td>
<td>34</td>
<td>48</td>
</tr>
<tr>
<td>$\geq 3198.9$</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td><strong>A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;473.4$</td>
<td>26</td>
<td>51</td>
</tr>
<tr>
<td>$473.4 - 726.3$</td>
<td>31</td>
<td>44</td>
</tr>
<tr>
<td>726.3</td>
<td>37</td>
<td>40</td>
</tr>
<tr>
<td><strong>E1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$p$-trend$^b$</td>
<td>94</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>E2 (mg/L)</td>
<td>P-trend</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td>&lt;59.1</td>
<td>1.00 (referent)</td>
</tr>
<tr>
<td></td>
<td>0.69 (0.86, 3.30)</td>
<td>1.75 (0.87, 3.53)</td>
</tr>
<tr>
<td></td>
<td>21.3 (1.04, 4.37)</td>
<td>2.13 (0.99, 4.59)</td>
</tr>
<tr>
<td></td>
<td>≥86.2</td>
<td>1.69 (0.36, 1.75)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.00 (referent)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.42 (0.20, 0.88)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.02 (0.00, 0.02)</td>
</tr>
</tbody>
</table>

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstanediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here).

†Additionally adjusted for BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

‡P-trend was calculated by assigning median values for each tertile of sex hormones and SHBG as a continuous variable in logistic regression models.
### Supplemental Table 6. Adjusted geometric means of sex steroid hormones and SHBG by chest hair density and Gleason score (N=234)

<table>
<thead>
<tr>
<th>Sex hormones</th>
<th>Serum (ng/dl)</th>
<th>( \text{Gleason score} &lt; 7 ) (N=130)</th>
<th>( \text{Gleason score} \geq 7 ) (N=104)</th>
<th>( \text{P-value})</th>
<th>( \text{P-value})</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>130</td>
<td>469.2 (417.0, 527.9) (n=57)</td>
<td>439.9 (397.2, 487.1) (n=73)</td>
<td>0.449</td>
<td>0.544</td>
</tr>
<tr>
<td>DHT</td>
<td>130</td>
<td>52.1 (46.9, 57.9)</td>
<td>50.7 (46.2, 55.5)</td>
<td>0.706</td>
<td>0.906</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>130</td>
<td>510.2 (442.9, 567.9)</td>
<td>544.0 (481.3, 614.9)</td>
<td>0.532</td>
<td>0.335</td>
</tr>
<tr>
<td>A</td>
<td>130</td>
<td>74.1 (65.5, 83.8)</td>
<td>70.2 (63.2, 78.1)</td>
<td>0.548</td>
<td>0.836</td>
</tr>
<tr>
<td>E1</td>
<td>130</td>
<td>5.5 (4.9, 6.1)</td>
<td>5.5 (5.0, 6.0)</td>
<td>0.990</td>
<td>0.049</td>
</tr>
<tr>
<td>E2</td>
<td>130</td>
<td>3.2 (2.9, 3.6)</td>
<td>3.1 (2.8, 3.4)</td>
<td>0.699</td>
<td>0.521</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>130</td>
<td>147.1 (131.8, 164.1)</td>
<td>142.1 (129.2, 156.2)</td>
<td>0.662</td>
<td>0.268</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>130</td>
<td>13.5 (11.9, 15.2)</td>
<td>12.8 (11.5, 14.2)</td>
<td>0.555</td>
<td>0.116</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>130</td>
<td>32.8 (29.5, 35.4)</td>
<td>32.9 (29.5, 35.4)</td>
<td>0.852</td>
<td>0.381</td>
</tr>
<tr>
<td>Free T</td>
<td>130</td>
<td>11.5 (10.4, 12.7)</td>
<td>10.8 (9.9, 11.8)</td>
<td>0.379</td>
<td>0.759</td>
</tr>
<tr>
<td>Free E2</td>
<td>130</td>
<td>0.09 (0.08, 0.10)</td>
<td>0.09 (0.08, 0.09)</td>
<td>0.748</td>
<td>0.347</td>
</tr>
</tbody>
</table>

### Adjacent normal prostate tissue (pg/g W)

| T            | 130          | 210.5 (189.0, 234.5) | 209.7 (191.0, 230.2) | 0.958 | 0.388 |
| DHT          | 130          | 6667.3 (6148.5, 7239.9) | 6095.1 (5682.5, 6537.6) | 0.128 | 0.630 |
| 3α-diol-G    | 129          | 2644.1 (2362.7, 2939.0) | 2531.8 (2296.8, 2791.0) | 0.594 | 0.543 |
| A            | 122          | 555.1 (489.4, 629.6) | 583.6 (521.3, 653.4) | 0.588 | 0.473 |
| E1           | 122          | 73.9 (65.2, 83.7) | 69.5 (62.3, 77.5) | 0.495 | 0.155 |
| E2           | 122          | 46.9 (41.2, 53.5) | 45.0 (40.1, 50.4) | 0.651 | 0.648 |
| T/E2 Ratio   | 122          | 4.4 (3.8, 5.0) | 4.5 (4.0, 5.0) | 0.760 | 0.192 |
| A/E1 Ratio   | 118          | 7.5 (6.4, 8.8) | 8.5 (7.4, 9.8) | 0.272 | 0.044 |

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstenediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (5 sites, not listed here), BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

*P-values were calculated for a global test of differences in geometric means.

*P-values were calculated for the multiplicative interaction between balding status and Gleason score.
### Supplemental Table 7. Adjusted* geometric means of sex steroid hormones and SHBG by chest hair density and race (N=231)

<table>
<thead>
<tr>
<th>Serum (ng/dl)</th>
<th>European American (N=126)</th>
<th>African American (N=105)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None/Sparsely</td>
<td>Moderate/Densely</td>
</tr>
<tr>
<td>T</td>
<td>(n=40)</td>
<td>(n=86)</td>
</tr>
<tr>
<td>T</td>
<td>407.4 (358.4, 463.1)</td>
<td>422.4 (367.9, 460.0)</td>
</tr>
<tr>
<td>DHT</td>
<td>45.5 (40.4, 51.4)</td>
<td>45.6 (42.1, 49.4)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>430.3 (362.5, 510.7)</td>
<td>513.8 (458.5, 575.8)</td>
</tr>
<tr>
<td>A</td>
<td>76.9 (66.9, 80.4)</td>
<td>60.0 (62.0, 74.6)</td>
</tr>
<tr>
<td>E1</td>
<td>4.7 (4.2, 5.2)</td>
<td>4.8 (4.4, 5.1)</td>
</tr>
<tr>
<td>E2</td>
<td>2.6 (2.3, 3.0)</td>
<td>2.7 (2.5, 2.9)</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>155.2 (136.6, 176.4)</td>
<td>156.6 (143.8, 170.5)</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>16.4 (14.2, 18.9)</td>
<td>14.2 (12.9, 15.7)</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>30.4 (27.1, 34.1)</td>
<td>31.6 (29.2, 34.0)</td>
</tr>
<tr>
<td>Free T</td>
<td>10.1 (9.0, 11.4)</td>
<td>10.5 (9.7, 11.3)</td>
</tr>
<tr>
<td>Free E2</td>
<td>0.07 (0.07, 0.08)</td>
<td>0.08 (0.07, 0.08)</td>
</tr>
</tbody>
</table>

### Adjacent normal prostate tissue (pg/g W)

<table>
<thead>
<tr>
<th>Serum (ng/dl)</th>
<th>European American (N=126)</th>
<th>African American (N=105)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None/Sparsely</td>
<td>Moderate/Densely</td>
</tr>
<tr>
<td>T</td>
<td>(n=40)</td>
<td>(n=86)</td>
</tr>
<tr>
<td>T</td>
<td>214.4 (162.0, 244.3)</td>
<td>210.9 (193.4, 229.9)</td>
</tr>
<tr>
<td>DHT</td>
<td>657.5 (596.2, 726.5)</td>
<td>641.9 (602.7, 685.4)</td>
</tr>
<tr>
<td>3α-diol-G</td>
<td>258.6 (224.5, 297.9)</td>
<td>273.2 (248.5, 300.3)</td>
</tr>
<tr>
<td>A</td>
<td>626.5 (530.2, 740.2)</td>
<td>557.5 (497.7, 624.5)</td>
</tr>
<tr>
<td>E1</td>
<td>59.0 (52.0, 66.8)</td>
<td>67.8 (62.3, 73.9)</td>
</tr>
<tr>
<td>E2</td>
<td>44.6 (38.8, 51.3)</td>
<td>44.8 (40.7, 49.3)</td>
</tr>
<tr>
<td>T/E2 Ratio</td>
<td>4.8 (4.2, 5.5)</td>
<td>4.6 (4.2, 5.0)</td>
</tr>
<tr>
<td>A/E1 Ratio</td>
<td>10.8 (9.1, 12.5)</td>
<td>8.2 (7.3, 9.3)</td>
</tr>
</tbody>
</table>

Abbreviations: T, testosterone; DHT, dihydrotestosterone; 3α-diol-G, 3α-androstenediol glucuronide; A, androstenedione; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin.

*Adjusted for age at surgery (year, continuous), study site (5 sites, not listed here), BMI (<25.0, 25.0–29.9, ≥30.0 kg/m²), education (less than high school, high school/technical school, college or higher, unknown), smoking status (never, former, current, unknown) and regular alcohol use (never, former, current, unknown).

P-values were calculated for a global test of differences in geometric means.

P-values were calculated for the multiplicative interaction between balding status and race (European American vs. African American).
Supplemental Fig 1. Modified Norwood-Hamilton Scale used to score hair loss patterns in NCI Prostate Tissue Study

No baldness

Vertex + Frontal baldness

Frontal baldness